Forex
RBC Slashes Target Price for Lakefront Biotherapeutics by 7% Amid Market Volatility
Royal Bank of Canada (RBC) has reduced its target price for Lakefront Biotherapeutics American Depositary Shares (LKFT) from $28.00 to $26.00 in a recent note, according to MarketBeat.
This adjustment comes as part of RBC's ongoing analysis of the biotechnology company's stock performance. The brokerage currently holds a 'sector perform' rating on LKFT's shares.
The new price target suggests a potential downside of 7.01% from LKFT's previous close, which was $27.96. This is based on RBC's assessment of the company's current market value and growth prospects.